Among the proteins of therapeutic interest in Alzheimer’s disease and capable of activating a pleiotropic prodrug to form an active ingredient, AChE and butyrylcholinesterase (BuChE) are prime targets. The gene discussed is ACHE; the disease is early-onset autosomal dominant Alzheimer disease.